Research AbstractThe impact of innovative medicines on healthcare costs in Canada 1990 to 2024: $20 billion cumulative annual variation in spending on patent drugs saved $70 billion in overall public healthcare expenditure. By Editor / 4 May 2026 Brett J Skinner, PhD | Founder and CEO, CHPI; Editor-in-Chief, CHPJ | ABSTRACT – Few
Research AbstractReimbursement recommendations for new medicines in Canada: current trends in an uncertain era By Editor / 19 April 2026 Nigel S. B. Rawson, PhD | Affiliated scholar/Senior fellow, Canadian Health Policy Institute, Macdonald-Laurier Institute,
Research AbstractCanada’s medication spending has been relatively low; may need to be reconsidered because of US “most-favored nation” pharma pricing policy By Editor / 9 March 2026 Gerry Jeffcott | 3Sixty Public Affairs | ABSTRACT – Background: Public discourse often frames innovative
Research AbstractDoes Canada pay its fair share of the global cost of pharmaceutical innovation? By Editor / 5 February 2026 Brett J Skinner, PhD | CEO, CHPI; Editor, CHPJ | ABSTRACT – The global cost
Research AbstractThe Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications By Editor / 29 January 2026 Yanick Labrie, MA | Health Economist, Yanick Labrie Consultant Inc. | ABSTRACT – Seasonal influenza
Research AbstractBulk purchasing for innovative pharmaceuticals – proceed with caution By Editor / 19 December 2025 Neil Palmer | Independent Consultant | ABSTRACT – The promise of substantial additional cost savings
Research AbstractNet direct expenditure on patented medicines by public drug plans in 10 Canadian provinces in 2023 By Editor / 18 December 2025 Brett Skinner, PhD | CEO CHPI, Editor CHPJ | ABSTRACT – Canada’s federal, provincial, and
